- Home
- ETNB vs NAVI Comparison
ETNB vs NAVI Comparison
Compare ETNB & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- NAVI
- Stock Information
- Founded
- ETNB 2018
- NAVI 1973
- Country
- ETNB United States
- NAVI United States
- Employees
- ETNB N/A
- NAVI N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- NAVI Investment Bankers/Brokers/Service
- Sector
- ETNB Health Care
- NAVI Finance
- Exchange
- ETNB Nasdaq
- NAVI Nasdaq
- Market Cap
- ETNB 1.5B
- NAVI 1.2B
- IPO Year
- ETNB 2019
- NAVI N/A
- Fundamental
- Price
- ETNB $10.08
- NAVI $13.51
- Analyst Decision
- ETNB Strong Buy
- NAVI Hold
- Analyst Count
- ETNB 8
- NAVI 7
- Target Price
- ETNB $26.43
- NAVI $13.64
- AVG Volume (30 Days)
- ETNB 2.2M
- NAVI 548.6K
- Earning Date
- ETNB 08-04-2025
- NAVI 07-23-2025
- Dividend Yield
- ETNB N/A
- NAVI 4.75%
- EPS Growth
- ETNB N/A
- NAVI N/A
- EPS
- ETNB N/A
- NAVI 0.52
- Revenue
- ETNB N/A
- NAVI $699,000,000.00
- Revenue This Year
- ETNB N/A
- NAVI N/A
- Revenue Next Year
- ETNB N/A
- NAVI $2.85
- P/E Ratio
- ETNB N/A
- NAVI $26.01
- Revenue Growth
- ETNB N/A
- NAVI N/A
- 52 Week Low
- ETNB $4.16
- NAVI $10.53
- 52 Week High
- ETNB $11.84
- NAVI $16.97
- Technical
- Relative Strength Index (RSI)
- ETNB 57.88
- NAVI 53.15
- Support Level
- ETNB $9.66
- NAVI $13.10
- Resistance Level
- ETNB $10.58
- NAVI $14.00
- Average True Range (ATR)
- ETNB 0.55
- NAVI 0.29
- MACD
- ETNB -0.09
- NAVI -0.06
- Stochastic Oscillator
- ETNB 58.39
- NAVI 45.81
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.